Skip to main content

Super navigation

  • Now approved in the US: VYVGART
  • Newsroom
    • The Latest
    • Press releases
    • argenx Stories
    • Downloadable assets
A
A

Main navigation additional

  • Home
  • Contact us
  • Home
  • Patients
    • Our commitment
    • Disease areas
    • Patient stories
    • MyRealWorld MG
    • Clinical trials
    • Patient Access
    • Resources
  • Pipeline
    • Our pipeline
    • Partnered programs
    • Publications
  • Innovation
    • Science of collaboration
    • IIP
    • Case studies
    • Academic collaborators
    • Antibody engineering
    • Partnering opportunities
  • Products
  • Investors
    • Stock information
    • Events & presentations
    • Financial Reports
    • Shareholder meetings
    • Corporate governance
    • AFM filings
    • SEC filings
    • Analyst coverage
  • Careers
    • Dare to do more
    • Join argenx
    • Benefits
    • Employee stories
  • Newsroom
    • The Latest
    • argenx Stories
    • Press releases
    • Downloadable assets
  • About
    • One Team
    • Values
    • Management team
    • Board of directors
    • Grants
    • Ethics and Responsibility
    • Contact us
Home

Secondary navigation additional

  • Contact

Secondary/mobile navigation

  • Home
  • Patients
    • Our commitment
    • Disease areas
    • Patient stories
    • MyRealWorld MG
    • Clinical trials
    • Patient Access
    • Resources
  • Pipeline
    • Our pipeline
    • Partnered programs
    • Publications
  • Innovation
    • Science of collaboration
    • IIP
    • Case studies
    • Academic collaborators
    • Antibody engineering
    • Partnering opportunities
  • Products
  • Investors
    • Stock information
    • Events & presentations
    • Financial Reports
    • Shareholder meetings
    • Corporate governance
    • AFM filings
    • SEC filings
    • Analyst coverage
  • Careers
    • Dare to do more
    • Join argenx
    • Benefits
    • Employee stories
  • Newsroom
    • The Latest
    • argenx Stories
    • Press releases
    • Downloadable assets
  • About
    • One Team
    • Values
    • Management team
    • Board of directors
    • Grants
    • Ethics and Responsibility
    • Contact us

Breadcrumb

  1. Home
  2. Press Releases

Press Releases

  • (-) Any
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
Reset

2019

July 25, 2019
argenx to report half year 2019 financial results and second quarter business update on August 1, 2019
May 29, 2019
argenx to Present at Upcoming Investor Conferences
May 27, 2019
argenx announces publication of efgartigimod Phase 2 myasthenia gravis trial results in Neurology
May 21, 2019
argenx announces pipeline expansion and “argenx 2021” vision to build integrated immunology company at 2019 R&D Day
May 14, 2019
argenx to Host R&D Day on May 22, 2019
May 8, 2019
argenx reports first quarter 2019 financial results and provides business update
May 7, 2019
argenx to Present at Bank of America Merrill Lynch 2019 Health Care Conference
May 6, 2019
argenx announces results of Annual General Meeting of Shareholders
March 25, 2019
argenx announces Annual General Meeting of Shareholders on May 7, 2019
March 13, 2019
argenx to receive first clinical milestone payment for product candidate developed
March 3, 2019
argenx to Present at Cowen and Company 39th Annual Health Care Conference
February 27, 2019
argenx reports fourth quarter business update and full year 2018 financial results

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Current page 9
  • Page 10
  • Page 11
  • Page 12
  • Page 13
  • …
  • Next page Next ›
  • Last page Last »
TwitterFacebookLinkedInWhatsApp
Home
  • Home
  • Contact us

Footer navigation

  • Home
  • Patients
    • Our commitment
    • Disease areas
    • Patient stories
    • MyRealWorld MG
    • Clinical trials
    • Patient Access
    • Resources
  • Pipeline
    • Our pipeline
    • Partnered programs
    • Publications
  • Innovation
    • Science of collaboration
    • IIP
    • Case studies
    • Academic collaborators
    • Antibody engineering
    • Partnering opportunities
  • Products
  • Investors
    • Stock information
    • Events & presentations
    • Financial Reports
    • Shareholder meetings
    • Corporate governance
    • AFM filings
    • SEC filings
    • Analyst coverage
  • Careers
    • Dare to do more
    • Join argenx
    • Benefits
    • Employee stories
  • Newsroom
    • The Latest
    • argenx Stories
    • Press releases
    • Downloadable assets
  • About
    • One Team
    • Values
    • Management team
    • Board of directors
    • Grants
    • Ethics and Responsibility
    • Contact us
2022 © argenx
Disclaimer
Privacy policy
Regulations